Plain-English translation of NCT06598527 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining a specialized radiation treatment called stereotactic body radiotherapy (SBRT) with immunotherapy and before surgery works better than immunotherapy and alone for people with stage II-III non-small cell lung cancer. One group will receive the radiation followed by the medication combined with platinum-based , while the other group will receive the medication and without radiation. All participants will then have surgery to remove the lung tumor.
Doctors want to know if adding targeted radiation to this immunotherapy approach can help more patients with lung cancer stay cancer-free longer. This medication has shown promise in treating lung cancer, and researchers believe combining it with radiation might improve outcomes before surgery.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two treatment groups. One group receives focused radiation to the lung tumor, then begins immunotherapy combined with given every three weeks for two cycles. The other group receives the same immunotherapy and for three cycles without radiation first. Between 4–6 weeks after your last dose, you will have surgery to remove the tumor. Throughout the trial, you will have imaging scans and blood tests to monitor how well the treatment is working and to check for side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China